Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by progressive and partially reversible airflow limitation, and it is among the leading causes of mortality worldwide.[@b1-copd-11-543] COPD is a multicomponent disease, and patients present a range of comorbidities that have an impact on prognosis and may increase the risk of mortality.[@b2-copd-11-543] The effects of COPD on respiratory and physical function have been well studied; moreover, due to the heavy burden of psychological disturbance, psychiatric morbidity, and disability in daily life, the mental health of COPD patients has received growing attention in recent years.[@b3-copd-11-543],[@b4-copd-11-543] The prevalence of cognitive impairment in patients with COPD ranges from 12% to 88%[@b5-copd-11-543] and is associated with depression, poor quality of life, which may affect patients' ability to manage their disease, and reduced compliance with medication and oxygen therapy,[@b6-copd-11-543],[@b7-copd-11-543] leading to adverse clinical outcomes.[@b8-copd-11-543]--[@b11-copd-11-543] Therefore, cognitive function as well as emotional function are important aspects of the overall clinical care of patients with COPD.

It has been suggested that a multidimensional assessment and personalized disease management approach could be an optimal strategy for addressing comorbidities, self-management education, and risk factor modification in COPD patients.[@b7-copd-11-543] The early identification of cognitive dysfunction is critical if outcomes are to be improved in this population, and an understanding of the characteristics associated with a higher risk of cognitive impairment may assist health care professionals to address this challenge.

The primary aim of this study was to examine the cross-sectional prevalence of cognitive impairment in an unselected population of COPD patients; the secondary objective was to determine the relationships between cognitive impairment and major demographic and clinical variables, such as lung function, depression, and quality of life.

Materials and methods
=====================

Study design and sample
-----------------------

The present study is a post hoc analysis of a cross-sectional, observational study conducted in respiratory medicine departments and primary care centers in Spain.[@b11-copd-11-543] This study was aimed at examining the prevalence of depressive symptoms and moderate-to-severe depression in COPD and included ambulatory patients who were 40 years of age or older, with stable COPD (confirmed by postbronchodilator forced expiratory volume in 1 second/forced vital capacity \<70% and absence of exacerbations in the previous 3 months). All patients that completed the mini-mental state examination (MMSE) were included in this post hoc analysis. The study was approved by the Institutional Ethics Committee of the Hospital Clinic (Barcelona, Spain) and was conducted in accordance with the principles of the Declaration of Helsinki. Prior to participation, all patients signed written documentation that the informed consent process was completed.

Study assessments
-----------------

Investigators recorded patients' sociodemographic data and clinical information on COPD severity using the Modified Medical Research Council Dyspnea scale[@b12-copd-11-543] and the Body mass index, airflow Obstruction, Dyspnea and Exacerbations (BODEx) index,[@b13-copd-11-543] comorbidity according to the Charlson index,[@b14-copd-11-543] exacerbations in the previous year, and treatment. Cognitive status was assessed by the MMSE,[@b15-copd-11-543],[@b16-copd-11-543] widely used to screen for cognitive impairment. This instrument explores spatial and temporal orientation, registration, attention, and calculation, recall, language, and visual construction in 12 items and 30 questions. A correct answer to one question was given 1 score point (total from 0 to 30). A score of less than 27 indicated cognitive impairment.[@b17-copd-11-543]

Depressive symptoms were measured using the short Beck Depression Inventory questionnaire.[@b18-copd-11-543],[@b19-copd-11-543] This tool is a 13-item self-administered inventory that assesses affective, cognitive, motivational, and vegetative symptoms of depression. Items use a 4-point scale that ranges from 0 to 3 and a total score is calculated by adding up the item responses. An additional question was included about suicidal ideation and suicidal attempts.

Health-related quality of life was assessed by the generic EuroQoL-5 dimensions (EQ-5D) questionnaire and the specific COPD Assessment Test (CAT). The EQ-5D consists of a 5-item descriptive system (including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), with each item rated as no problems, some problems, or severe problems, and an overall health state score for the day of the assessment, measured on a visual analog scale (0--100; 100 represents best overall health).[@b20-copd-11-543] The CAT is a short, specific quality of life questionnaire for measuring the impact of COPD on the patient's well-being and daily life. It consists of eight items, each presented as a 6-point semantic differential scale, providing a score out of 40, indicating the impact of the disease.[@b21-copd-11-543] We used the validated Spanish version of CAT.[@b22-copd-11-543] Physical activity was measured by asking patients how many minutes, on average, they walked every weekday, as previously described.[@b23-copd-11-543],[@b24-copd-11-543] Depending on their daily walking activity, patients were classified into three groups: patients who walked \<30 minutes, patients who walked between 30 and 60 minutes, and patients who walked ≥60 minutes.

Statistical analysis
--------------------

Continuous variables were expressed as the mean and the standard deviation. Categorical values were described as absolute and relative frequencies. Fisher's exact test was used for comparisons of qualitative variables, with the Bonferroni correction for all pairwise comparisons. Student's *t*-test was used to determine the relationship between qualitative variables by group. Odds ratio (OR) univariates were calculated by logistic regression to evaluate the different risks contemplated in the study, including all demographic, clinical, and questionnaires variables. Only significant associations are shown in the [Tables 2](#t2-copd-11-543){ref-type="table"} and [3](#t3-copd-11-543){ref-type="table"}. After stepwise analysis, the various adjusted ORs were calculated using multivariate logistic regression. The first model was developed with cognitive status as a dependent variable and all variables that showed a significant association with cognition in univariate analysis as independent variables (model 1). A second model (model 2) excluded any variables derived from the use of the questionnaires from the independent variables. The objective of model 2 was to identify the factors associated with cognitive impairment that could be identified in routine clinical practice without the administration of questionnaires.

All statistical tests were considered significant when *P* was \<0.05. Statistical analyses were performed using SAS version 9.1.3 Service Pack 3 software (SAS Institute Inc., Cary, NC, USA).

Results
=======

Sample characteristics and cognitive status
-------------------------------------------

Of 1,273 screened patients, 333 had not had the MMSE evaluation and were excluded from the analysis. Both populations (excluded and included ones) were compared and their characteristics are described in [Table 1](#t1-copd-11-543){ref-type="table"}. Included patients were predominantly male, with an age ranging from 40 to 90 years. A total of 370 patients (39.4%) scored below the threshold of 27 for suspicion of mild cognitive impairment (MCI; [Figure 1](#f1-copd-11-543){ref-type="fig"}). Patients with MMSE scores \<27 were older, had a lower level of formal education, had heavier smoking exposure, presented more respiratory symptoms, had more frequently domiciliary oxygen, suffered a higher number of and more severe exacerbations during the previous year, and had a greater comorbidity burden. In addition, higher levels of depression, more suicidal ideation, poorer quality of life, and less physical activity were more frequent in cognitively impaired patients.

Factors associated with the presence of cognitive impairment
------------------------------------------------------------

In the univariate analysis, cognitive impairment was associated with higher age, lower educational level, worse lung function and more severe COPD, more frequent respiratory symptoms and exacerbations, and oxygen therapy requirement. Higher comorbidity burden, more depressive symptoms, and more impaired health status (EQ-5D and CAT) were also associated with cognitive impairment. Higher levels of physical activity were associated with better cognitive function ([Table 2](#t2-copd-11-543){ref-type="table"}).

In the multivariate analysis, only educational level and the EQ-5D social tariff were independently and significantly associated with cognitive impairment ([Table 2](#t2-copd-11-543){ref-type="table"}). When the analysis was limited to the usual demographic and clinical variables, and the questionnaires were excluded from the model, the significant factors in the multivariate analysis were educational level, history of exacerbations, the BODEx index, and the Charlson comorbidity index ([Table 3](#t3-copd-11-543){ref-type="table"}).

Discussion
==========

COPD is a multicomponent inflammatory disease that affects physical and nonphysical functions, one of which is cognition. In our study, we found some degree of cognitive impairment in almost 40% of unselected COPD patients, as determined by a MMSE score \<27. Previous estimates of cognitive dysfunction in COPD patients ranged from 12% to 88%, depending on the study population and the tools used for neuropsychological assessment.[@b5-copd-11-543],[@b9-copd-11-543] A recent study in a very similar population (including not only elderly patients, but also young patients) to ours[@b17-copd-11-543] found MCI in 36% of COPD patients after comprehensive neuropsychological testing. The authors reported that a MMSE score of 27 provided optimal maximum accuracy and a diagnostic cutoff (\<27 indicated impairment), with 97% specificity and 73% of patients correctly classified. However, they also found that the Montreal Cognitive Assessment performed better as a screening test for detecting MCI in patients with COPD. So, this threshold for mild impairment is not necessarily indicative of a clinically significant cognitive decline associated with functional impairment, but could serve as an early identification of an affected cognitive function.

Cognitive symptoms are core symptoms in many mental disorders;[@b25-copd-11-543] they impact on cognitive functioning, which deteriorates as patients get older, particularly after the age of 60.[@b26-copd-11-543] COPD patients score lower on standard cognitive performance tests over time, compared with individuals of the same age without the disease.[@b27-copd-11-543] One hypothesis for this accelerated decline in COPD patients is altered brain perfusion.[@b28-copd-11-543] Changes in brain perfusion due to hypoxemia in subjects with severe COPD may increase cognitive impairment.[@b29-copd-11-543] In our population, more cognitively affected patients were receiving domiciliary oxygen that could be a correlate of higher disease severity and sustained periods of hypoxemia. In contrast, a recent study indicated that long-term home oxygen therapy allowed to preserve cognitive functions from the COPD-induced deterioration,[@b30-copd-11-543] so the role of supplemental oxygen in preventing COPD-induced cognitive deterioration is still controversial. Indeed, other factors, such as hypercapnia or oxidative stress, may also be involved.[@b31-copd-11-543] Other authors have suggested that intermittent and continuous hypoxia resulting from poor lung function may lead to transient deficits in neurotransmitter metabolism in the central nervous system.[@b32-copd-11-543]--[@b34-copd-11-543] Several mechanisms, then, appear to be involved in cognitive decline in this population. Prospective neuroimaging studies are required to characterize brain changes and corresponding disturbances in cognitive function in these patients over time.

Cognitive impairment represents a critical health care burden in terms of costs.[@b35-copd-11-543] Individuals with MCI have a higher risk of developing dementia than the general population.[@b36-copd-11-543] Moreover, cognitive dysfunction in COPD has been associated with poorer outcomes and even with an increase in disability and mortality.[@b8-copd-11-543],[@b37-copd-11-543],[@b38-copd-11-543] Thus, it is essential that this condition is identified early in COPD patients, in order to prevent or delay progression to clinical dementia or increased morbidity. If the factors affecting cognition are recognized, cognitive impairment may be detected earlier and COPD patients at higher risk may be identified. In our study, the multivariate analysis showed that educational level and quality of life assessed by EQ-5D were significantly and independently associated with the presence of cognitive impairment. However, the use of health-related quality of life or other questionnaires is not a routine practice in most primary care offices, so we ran a multivariate model, discarding the scores of these questionnaires and including only demographic and clinical variables. In this model, cognitive impairment was associated with exacerbations in the previous year, the severity of COPD measured by the BODEx index, and a higher comorbidity burden.

Exacerbations in COPD are of great importance. They have been associated with increased health care costs,[@b39-copd-11-543] a significant decline in health status,[@b40-copd-11-543] and substantial mortality.[@b41-copd-11-543] Our results suggest that frequent exacerbations also have negative consequences on cognitive function. This is in line with a previous study that investigated the cognitive function of COPD patients who were hospitalized following an acute exacerbation. These patients had significantly poorer cognitive function compared with control participants 3 months after discharge from the hospital.[@b10-copd-11-543] Other studies have shown that cognitive impairment during the exacerbation period resolves during periods of stability.[@b42-copd-11-543]--[@b44-copd-11-543] More exacerbations and increased COPD severity could reflect the poorer compliance with medication associated with cognitive impairment.[@b6-copd-11-543],[@b7-copd-11-543] The systemic inflammation seen in severe COPD and during acute exacerbations[@b45-copd-11-543] may participate in neurocognitive impairment via a direct neurotoxic effect or by affecting cerebral atherosclerosis.[@b9-copd-11-543] A high comorbidity burden may also contribute to persistent brain injury: multiple concomitant diseases, such as cerebrovascular disease and related mechanisms, including endothelial dysfunction and oxidation, may lead to neuronal death, synaptic dysfunction, and cognitive impairment.[@b46-copd-11-543]

All these data confirm that the cognitive impairment that occurs in COPD patients is associated with disease severity. Neuropsychiatric assessment should become a routine part of the diagnostic procedure for these patients, to help physicians grade the overall impact of COPD and determine the most effective treatment and strategies.

The cross-sectional design of our study limits any type of causal inferences, and the directionality between COPD and cognition remains unclear. Despite the frequent use of the MMSE in clinical research and practice, this tool for cognitive impairment detection could have missed key domains of cognition often affected in COPD (ie, executive functioning). An additional limitation of our study is the lack of data on our patients' medical treatment. As treatment may have great impact on the symptom burden and mental health of the patients, such information should be collected in future studies. In particular, prospective studies are urgently needed to determine the most effective behavioral and medical interventions for reducing the risk of poor neurocognitive outcomes in patients with COPD.

Conclusion
==========

Cognitive impairment is common in COPD and has important clinical implications. Early detection of cognitive decline is crucial, in view of its association with poorer COPD outcomes, including increased mortality, and patients with frequent exacerbations and or when the BODEx index appears concerning the clinician may want to ask the patient and/or caregivers about cognitive function. These patients may need more individualized educational and care interventions to help them manage their daily lives. Clinicians must involve family caregivers in the care plan of patients with severe COPD and cognitive deficits.
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**Abbreviation:** MMSE, mini-mental state examination.](copd-11-543Fig1){#f1-copd-11-543}

###### 

Characteristics of all patients with and without cognitive impairment according to MMSE scores

  Variable                                                                      Excluded patients                                        Included patients   MMSE \<27     MMSE ≥27        *P*-value
  ----------------------------------------------------------------------------- -------------------------------------------------------- ------------------- ------------- --------------- ----------------------------------------------------
  Sex, males (n, %)                                                             233 (73.1%)[a](#tfn1-copd-11-543){ref-type="table-fn"}   762 (81.6%)         299 (81.7%)   463 (81.5%)     \>0.99
  Age, years (mean, SD)                                                         66.8 (9.4)                                               67.7 (10.0)         69.6 (9.5)    66.5 (10.1)     \<0.001
  Coexistence (n, %)                                                                                                                                                                       
   Alone                                                                        55 (17.1%)                                               121 (13.0%)         50 (13.6%)    71 (12.5%)      \<0.001[b](#tfn2-copd-11-543){ref-type="table-fn"}
   With partner                                                                 212 (66.0%)                                              646 (69.2%)         224 (61.0%)   422 (74.4%)     
   With family                                                                  47 (14.6%)                                               141 (15.1%)         75 (20.4%)    66 (11.6%)      
   Institutionalized                                                            1 (0.3%)                                                 12 (1.3%)           8 (2.2%)      4 (0.7%)        
   With professional caregiver                                                  6 (1.9%)                                                 14 (1.5%)           10 (2.7%)     4 (0.7%)        
  Educational level (n, %)                                                                                                                                                                 
   Basic literacy                                                               47 (14.7%)[a](#tfn1-copd-11-543){ref-type="table-fn"}    74 (7.9%)           42 (11.4%)    32 (5.7%)       \<0.001[c](#tfn3-copd-11-543){ref-type="table-fn"}
   Primary level                                                                190 (59.6%)                                              540 (57.9%)         251 (68.4%)   289 (51.1%)     
   Secondary level                                                              62 (19.4%)                                               193 (20.7%)         52 (14.2%)    141 (25.0%)     
   Completed university                                                         20 (6.3%)[a](#tfn1-copd-11-543){ref-type="table-fn"}     125 (13.4%)         22 (6.0%)     103 (18.2%)     
  COPD duration (mean, SD)                                                      10.4 (6.4)                                               11.6 (7.7)          12.9 (8.0)    10.8 (7.4)      \<0.001
  Active smoker (n, %)                                                          77 (25.8%)                                               206 (22.4%)         66 (18.4%)    140 (25.0%)     \>0.99
  Pack-years (mean, SD)                                                         37.1 (20.4)                                              39.5 (21.8)         42.3 (24.8)   37.7 (19.4)     0.002
  BMI (mean, SD)                                                                27.5 (4.7)                                               27.8 (4.7)          27.9 (4.7)    27.7 (4.7)      0.52
  Postbronchodilator spirometry (mean, SD)                                                                                                                                                 
   FVC, mL                                                                      2,945 (977)                                              3,046 (977)         2,912 (922)   3,132 (1,001)   0.001
   FVC, %                                                                       65.4 (21.2)[a](#tfn1-copd-11-543){ref-type="table-fn"}   71.0 (17.0)         71.3 (15.8)   70.8 (17.70)    0.55
   FEV~1~, mL                                                                   1,805 (846)                                              1,886 (852)         1,778 (767)   1,957 (897)     0.002
   FEV~1~, %                                                                    54.4 (21.0)                                              55.2 (17.8)         55.7 (17.9)   54.9 (17.7)     0.59
   FEV~1~/FVC                                                                   56.6 (16.0)                                              58.5 (20.9)         57.2 (13.8)   59.4 (24.4)     0.13
  Cough (n, %)                                                                  264 (85.7%)                                              770 (83.2%)         322 (89.7%)   448 (79.1%)     \<0.001
  Expectoration (n, %)                                                          233 (78.4%)                                              669 (73.0%)         286 (79.7%)   383 (68.7%)     \<0.001
  Dyspnea, (n, %)                                                               296 (94.0%)                                              891 (95.0%)         359 (97.5%)   532 (93.3%)     0.003
  mMRC dyspnea score (mean, SD)                                                 2.8 (0.9)                                                2.8 (0.9)           3.1 (0.9)     2.6 (0.9)       \<0.001
  Patient with exacerbations (n, %)                                             265 (79.6%)[a](#tfn1-copd-11-543){ref-type="table-fn"}   808 (86.0%)         351 (94.9%)   457 (80.2%)     \<0.001
  Number of hospital-treated exacerbations (emergency + admission) (mean, SD)   1.3 (0.5)[a](#tfn1-copd-11-543){ref-type="table-fn"}     1.4 (2.2)           1.8 (2.7)     1.0 (1.5)       \<0.001
  Oxygen therapy at home, (n, %)                                                65 (23.0%)                                               204 (23.4%)         130 (37.0%)   74 (14.2%)      \<0.001
  BODEx (mean, SD)                                                              2.7 (1.8)                                                2.8 (1.9)           3.3 (1.8)     2.4 (1.9)       \<0.001
  Charlson comorbidity index (mean, SD)                                         1.3 (1.4)[a](#tfn1-copd-11-543){ref-type="table-fn"}     1.4 (1.4)           1.6 (1.5)     1.0 (0.6)       \<0.001
  BDI score (mean, SD)                                                          9.3 (6.1)                                                9.0 (6.5)           11.7 (6.4)    7.2 (5.7)       \<0.001
  Suicidal ideation (n, %)                                                      29 (9.4%)                                                123 (13.1%)         78 (21.2%)    45 (7.9%)       \<0.001
  Health status according to EQ-5D (mean, SD)                                   57.9 (17.1)                                              57.4 (19.2)         52.4 (18.2)   60.5 (19.2)     \<0.001
  Social tariff EQ-5D (mean, SD)                                                0.6 (0.2)                                                0.6 (0.2)           0.5 (0.2)     0.7 (0.2)       \<0.001
  CAT score (mean, SD)                                                          21.6 (7.3)                                               21.6 (8.6)          25.2 (6.9)    19.3 (8.7)      \<0.001
  Physical activity grade (mean, SD)                                            4.1 (1.6)                                                4.3 (1.5)           3.7 (1.4)     4.6 (1.5)       \<0.001
  Minutes walked per day (mean, SD)                                             73.5 (68.2)[a](#tfn1-copd-11-543){ref-type="table-fn"}   64.2 (52.3)         56.1 (45.8)   68.8 (55.2)     0.001

**Notes:**

Excluded vs included patients.

Alone vs professional caregiver.

Basic literacy vs completed university.

**Abbreviations:** BDI, Beck Depression Inventory; BMI, body mass index; BODEx, Body mass index, airflow Obstruction, Dyspnea and Exacerbations index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQoL-5 dimensions; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; mMRC, Modified Medical Research Council scale; MMSE, mini-mental state examination; SD, standard deviation.

###### 

Factors associated with cognitive impairment in univariate and multivariate analysis

  Variable                                                     Univariate   Multivariate                                    
  ------------------------------------------------------------ ------------ -------------- --------- ------- -------------- ---------
  Age (per 5-year increment)                                   1.177        1.099--1.262   \<0.001                          
  Educational level (completed university vs basic literacy)   0.160        0.080--0.310   \<0.001   0.069   0.011--0.447   0.014
  Postbronchodilator FVC                                       0.977        0.963--0.991   0.001                            
  Postbronchodilator FEV~1~                                    0.975        0.959--0.991   0.003                            
  Cough                                                        2.290        1.540--3.410   \<0.001                          
  Expectoration                                                1.780        1.300--2.430   \<0.001                          
  Presence of dyspnea (yes vs no)                              2.850        1.360--5.960   0.005                            
  Exacerbations in the previous year (yes vs no)               4.570        2.750--7.570   \<0.001                          
  Oxygen therapy                                               3.180        1.070--9.440   0.037                            
  BODEx                                                        1.280        1.179--1.389   \<0.001                          
  Charlson comorbidity index                                   1.590        1.435--1.762   \<0.001                          
  BDI score                                                    1.125        1.098--1.152   \<0.001                          
  Suicide ideation                                             3.150        2.120--4.670   \<0.001                          
  Health status according to EQ-5D                             0.799        0.742--0.860   \<0.001                          
  Social tariff EQ-5D                                          0.971        0.965--0.977   \<0.001   0.967   0.950--0.983   \<0.001
  CAT score                                                    1.098        1.078--1.118   \<0.001                          
  Physical activity grade                                      0.648        0.587--0.715   \<0.001                          
  Minutes walked per day                                       0.994        0.991--0.998   0.001                            

**Abbreviations:** BDI, Beck Depression Inventory; BODEx, Body mass index, airflow Obstruction, Dyspnea and Exacerbations index; CAT, COPD Assessment Test; CI, confidence interval; EQ-5D, EuroQoL-5 dimensions; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; OR, odds ratio.

###### 

Factors associated with cognitive impairment in univariate and multivariate analysis, including only demographic and clinical variables

  Variable                                                     Univariate   Multivariate                                      
  ------------------------------------------------------------ ------------ -------------- --------- -------- --------------- -------
  Age (per 5-year increment)                                   1.177        1.099--1.262   \<0.001                            
  Educational level (completed university vs basic literacy)   0.160        0.080--0.310   \<0.001   0.063    0.010--0.394    0.010
  Postbronchodilator FVC                                       0.977        0.963--0.991   0.001                              
  Postbronchodilator FEV~1~                                    0.975        0.959--0.991   0.003                              
  Cough                                                        2.290        1.540--3.410   \<0.001                            
  Expectoration                                                1.780        1.300--2.430   \<0.001                            
  Dyspnea                                                      2.850        1.360--5.960   0.005                              
  Exacerbations                                                4.570        2.750--7.570   \<0.001   11.070   1.450--84.534   0.020
  Oxygen therapy                                               3.180        1.070--9.440   0.037                              
  BODEx                                                        1.280        1.179--1.389   \<0.001   1.261    1.049--1.515    0.014
  Charlson comorbidity index                                   1.590        1.435--1.762   \<0.001   1.412    1.118--1.783    0.004
  Suicide ideation                                             3.150        2.120--4.670   \<0.001                            
  Physical activity grade                                      0.648        0.587--0.715   \<0.001                            
  Minutes walked per day                                       0.994        0.991--0.998   0.001                              

**Abbreviations:** BODEx, Body mass index, airflow Obstruction, Dyspnea and Exacerbations index; CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; OR, odds ratio.
